Commander of Corona Countermeasures Headquarters in the Tehran metropolis, noting that today the country’s pharmaceutical industry has reached a very high level, said: “The commitment of the country’s pharmaceutical industry to quality and standard is unparalleled and we have never seen sacrificial of quality for quantity in this industry.

According to the public relations of Actover Group, Alireza Zali, during his visit to Actover factory, added: “The establishment of the Actoverco by the late Mostafa Naraghi before the revolution and when the presence of multinational companies in Iran was strong and there was a lot of competition, demonstrates his fearlessness and patriotism.”

He, by noting that the potential of collections such as Actoverco should be used more, explained: “Achieving global standards in the pharmaceutical industry has become more stringent. On the other hand, despite the political difficulties, scientific interaction with foreign partners is necessary and without the application of global experience, progress in the pharmaceutical industry is difficult. The fact that Actoverco cooperates with 10 international companies is very valuable and transfers technical knowledge to the country, and this should not be stopped.”

He added: “Youthism is another valuable event that has taken place in Actoverco and can lead to good things.”

Zali, noting that dependence on the import of pharmaceutical raw materials is one of the weaknesses of the country’s pharmaceutical industry, which causes a great deal of currency to leave the country, said: “We hope Actoverco, which has established a department for the production of raw materials for medicine, work stronger in this area. It’s a great coincidence that Actoverco is active in about 15 therapeutic areas, and of course Actoverco’s position could be much greater than this.”

He said: “Biohazardous drugs are another weakness of the country’s pharmaceutical industry, which of course some companies have entered this field, and in my opinion, if a company does not enter this field, it will lag behind the competition. Many new drugs will enter the market through Biohazard path.”

The Commander of Corona Countermeasures Headquarters in the Tehran metropolis emphasized: “the burden of diseases should be specified in a blueprint so that investors can enter the field of drug production with a better view. For example, asthma, lung diseases and COPD will be one of the main diseases in Iran in the upcoming years. In the field of cancer, the patterns of incidence have changed in Iran and world.”

He by mentioning that COVID-19 is a complex disease whose eradication is currently out of the question, elucidated: “We will be dealing with this disease for a long time and we are just witnessing the corona virus mutations. Therefore, pharmaceutical companies’ actions in the field of COVID-19 will be continuous. We are also waiting for the next COVID-19 waves and we should not note the current declining statistics. On the other hand, we do not have any definitive cure for COVID-19, although, fortunately, what is currently prescribed for the treatment of COVID-19 in the world is also prescribed in Iran and in this regard, we have no shortage of drugs such as Remdesivir, Favipiravir, Ivermectin and…”

The Commander of Corona Countermeasures Headquarters in the metropolis of Tehran, emphasizing the purchase of COVID-19 vaccines from reputable sources, highlighted: “to achieve the cumulative immunity and breaking the COVID-19 disease chain, we have no choice but vaccination. Vaccination will significantly reduce the incidence and mortality of COVID-19. Best case scenario, COVID-19 will eventually change from pandemic to endemic, so we must have both domestic and foreign vaccines and use the capacity of the private sector to supply vaccine.”